 |
Prospector
Profile
2-1-001
|
| |
| Cancer Therapeutics, Inc. |
NAICS |
541710 |
| 210 West Hansell Street
Thomasville, GA 31792 |
Description |
Biotechnology |
| (229) 403-1282 |
Employees |
0 |
| www.cancer-therapeutics.com. |
Revenue |
(mil) |
0.0149 |
| |
Income |
(mil) |
0.0620 |
| |
Assets |
(mil) |
0.0010 |
| |
Liability |
(mil) |
0.4730 |
| |
(for the year ended 2007-05-31) |
| |
|
Category:
Loss/Deficit
|
| |
|
Event:
Cancer Therapeutics, Inc., posted a net loss of $9,418 on net revenues of $75 for the three months ended November 30, 2007, much lower than the net loss of $20,876 on net revenues of $5,275 incurred during the three months ended November 30, 2006. At November 30, 2007, the Company's balance sheet showed an accumulated deficit of $3,007,404 and stockholders' deficit of $499,490.
|
| |
|
Intellectual Property:
The Company has proprietary processes or methods of growing and activating cells. The proprietary nature of these rest in the techniques developed by Walter Lewko, Ph.D., and Robert K. Oldham, M.D., the Company's principal scientists over the past 23 years. The Company has been able to develop protocols and procedures at its laboratory that allow for optimal conditions for successful storage in its Cryobank, t-cell harvesting and vaccine growth. Its procedures and processes have only come from many years of practice. The Company is able to foster conditions within the laboratory that allows for more successful t-cell harvesting, vaccine growth and Cryobank storage of tumors. However, the Company has not been able to apply for certain process patents because of a lack of capital, but the Company's principal scientists have specialized knowledge concerning the culture and activation of T-cells and the preparation of vaccines. This proprietary expertise is described within the Company's written standard operating procedures and research database. [SEC Filing 10-KSB 08-30-07]
|
| |
|
Description:
Cancer Therapeutics, Inc., is a biotherapy company that focuses on researching and developing biotherapy approaches for the treatment of cancer.
|
| |
|
Officers:
Chene Gardner (CEO & CFO); Michael Low (Sec.)
|
| |
|
Auditor:
Bouwhuis Morrill & Company LLC
|
| |
|
Securities:
Common Stock-Symbol CTHP.OB; OTC BB; 4,129,477 common shares outstanding as of January 8, 2008.
|
| |
| |
| |
| return to main page |
|
|
